[go: up one dir, main page]

HK1257101A1 - 治療性遞送囊泡 - Google Patents

治療性遞送囊泡

Info

Publication number
HK1257101A1
HK1257101A1 HK18116352.8A HK18116352A HK1257101A1 HK 1257101 A1 HK1257101 A1 HK 1257101A1 HK 18116352 A HK18116352 A HK 18116352A HK 1257101 A1 HK1257101 A1 HK 1257101A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic delivery
delivery vesicles
vesicles
therapeutic
delivery
Prior art date
Application number
HK18116352.8A
Other languages
English (en)
Inventor
Oscar WIKLANDER
Joel NORDIN
Edvard Smith
Karl-Henrik Grinnemo
Oscar Simonson
Andaloussi Samir El
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20296661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1257101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Publication of HK1257101A1 publication Critical patent/HK1257101A1/zh

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01C—ROTARY-PISTON OR OSCILLATING-PISTON MACHINES OR ENGINES
    • F01C1/00—Rotary-piston machines or engines
    • F01C1/30—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members
    • F01C1/34—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members
    • F01C1/344—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member
    • F01C1/3441—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member the inner and outer member being in contact along one line or continuous surface substantially parallel to the axis of rotation
    • F01C1/3442—Rotary-piston machines or engines having the characteristics covered by two or more groups F01C1/02, F01C1/08, F01C1/22, F01C1/24 or having the characteristics covered by one of these groups together with some other type of movement between co-operating members having the movement defined in group F01C1/08 or F01C1/22 and relative reciprocation between the co-operating members with vanes reciprocating with respect to the inner member the inner and outer member being in contact along one line or continuous surface substantially parallel to the axis of rotation the surfaces of the inner and outer member, forming the working space, being surfaces of revolution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01C—ROTARY-PISTON OR OSCILLATING-PISTON MACHINES OR ENGINES
    • F01C21/00—Component parts, details or accessories not provided for in groups F01C1/00 - F01C20/00
    • F01C21/10—Outer members for co-operation with rotary pistons; Casings
    • F01C21/102—Adjustment of the interstices between moving and fixed parts of the machine by means other than fluid pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Fluid Mechanics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
HK18116352.8A 2013-04-12 2018-12-20 治療性遞送囊泡 HK1257101A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1300271 2013-04-12

Publications (1)

Publication Number Publication Date
HK1257101A1 true HK1257101A1 (zh) 2019-10-11

Family

ID=20296661

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116352.8A HK1257101A1 (zh) 2013-04-12 2018-12-20 治療性遞送囊泡

Country Status (11)

Country Link
US (3) US11274139B2 (zh)
EP (2) EP3335721A1 (zh)
JP (3) JP6542197B2 (zh)
AU (1) AU2014251388B2 (zh)
CA (1) CA2910802A1 (zh)
DK (1) DK2983721T4 (zh)
ES (1) ES2662326T5 (zh)
HK (1) HK1257101A1 (zh)
PT (1) PT2983721T (zh)
SG (1) SG11201508433TA (zh)
WO (1) WO2014168548A2 (zh)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
ES2662326T5 (es) 2013-04-12 2021-08-04 Evox Therapeutics Ltd Vesículas de suministro terapéutico
CA2909356C (en) 2013-04-16 2023-09-12 Orbsen Therapeutics Limited Medical use of syndecan-2
US10624929B2 (en) 2014-05-18 2020-04-21 Children's Medical Center Corporation Methods and compositions relating to exosomes
GB201418562D0 (en) * 2014-10-20 2014-12-03 Univ London Queen Mary Peptides
EP3271396B1 (en) 2015-03-20 2022-03-16 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
KR20160130937A (ko) * 2015-05-04 2016-11-15 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법
KR101912310B1 (ko) * 2016-10-04 2018-10-26 주식회사 셀렉스라이프사이언스 페록시레독신 i 또는 ii 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 항산화용 약학적 조성물
US12133879B2 (en) 2015-05-04 2024-11-05 Ilias Biologics Inc. Exosomes for target specific delivery and methods for preparing and delivering the same
KR101900465B1 (ko) * 2016-10-13 2018-09-19 주식회사 셀렉스라이프사이언스 CRISPR-CAS family를 이용한 게놈 에디팅 툴을 엑소솜으로 전달하는 기술
KR101912315B1 (ko) * 2016-09-30 2018-10-26 주식회사 셀렉스라이프사이언스 Bax 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
WO2016178532A1 (ko) * 2015-05-04 2016-11-10 한국과학기술원 목적 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 이용하여 목적 단백질을 세포질로 전달시키는 방법
US10702581B2 (en) 2015-05-04 2020-07-07 Ilias Biologics Inc. Compositions containing protein loaded exosome and methods for preparing and delivering the same
WO2019035057A2 (en) * 2017-08-17 2019-02-21 Cellex Life Sciences, Incorporated EXOSOMES FOR TARGET-SPECIFIC DELIVERY AND METHODS OF PREPARATION AND ADMINISTRATION THEREOF
KR101877010B1 (ko) * 2016-09-30 2018-08-09 한국과학기술원 super-repressor-IκB 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 염증성 질환 예방 및 치료용 약학적 조성물
KR101912313B1 (ko) * 2016-09-30 2018-10-26 주식회사 셀렉스라이프사이언스 Cre 재조합 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 표적 유전자의 조건적 녹아웃 대립유전자를 생성하기 위한 조성물
MA45481A (fr) 2015-06-10 2018-04-18 Univ Texas Utilisation d'exosomes pour le traitement de maladies
CA2997811C (en) * 2015-10-01 2021-09-21 University Of Ottawa Exosome packaging of nucleic acids
WO2017054086A1 (en) * 2015-10-01 2017-04-06 Exerkine Corporation Treatment of genetic myopathies using bioengineered exosomes
BR112018009891A2 (pt) 2015-11-18 2018-12-26 University Of Georgia Research Foundation, Inc. vesículas extracelulares de célula neural
EP3922253A1 (en) * 2016-01-15 2021-12-15 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
GB2552460A (en) * 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
GB2552301A (en) * 2016-07-11 2018-01-24 Evox Therapeutics Ltd Metabolic drug loading of EVs
GB2552774A (en) * 2016-07-12 2018-02-14 Evox Therapeutics Ltd EV-Mediated delivery of binding protein-small molecule conjugates
GB2552473A (en) 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
CA3002520A1 (en) * 2016-09-30 2018-04-05 Cellex Life Sciences, Incorporated Compositions containing protein loaded exosome and methods for preparing and delivering the same
KR102120921B1 (ko) * 2017-02-10 2020-06-10 주식회사 일리아스바이오로직스 Gba 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 고셔병 예방 및 치료용 약학적 조성물
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2018173059A1 (en) 2017-03-21 2018-09-27 Exoprother Medical Ltd. Native cell derived vesicles containing tumor suppressor proteins for therapy
WO2018208670A1 (en) * 2017-05-08 2018-11-15 Trustees Of Tufts College EXTRACELLULAR VESICLES COMPRISING MEMBRANE-TETHERED TGF-β, COMPOSITIONS AND METHODS OF USE THEREOF
EP3622079A1 (en) 2017-05-08 2020-03-18 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
CA3069805A1 (en) 2017-07-14 2019-01-17 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
KR20200040818A (ko) * 2017-08-15 2020-04-20 칠드런'즈 메디컬 센터 코포레이션 정제된 중간엽 줄기 세포 엑소좀 및 그의 용도
EP3668552A4 (en) * 2017-08-17 2021-04-28 Ilias Biologics Inc. TARGET ADMINISTRATION EXOSOMES AND METHOD OF PREPARATION AND ADMINISTRATION
US20210163930A1 (en) 2017-08-21 2021-06-03 Resurgo Genetics Limited Methods of changing transcriptional output
GB201717446D0 (en) * 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
TR201720642A2 (tr) * 2017-12-18 2019-07-22 Univ Yeditepe Güdümlü kafe yüklü mi̇krovesi̇küler kanser i̇laci ve bunun geli̇şti̇ri̇lmesi̇ yöntemi̇
EP3728592B1 (en) 2017-12-22 2024-05-29 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
EP3728590A1 (en) 2017-12-22 2020-10-28 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
CN111448317A (zh) 2017-12-22 2020-07-24 罗氏创新中心哥本哈根有限公司 包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸
GB201802163D0 (en) * 2018-02-09 2018-03-28 Evox Therapeutics Ltd Compositions for EV storage and formulation
CA3091478A1 (en) 2018-02-17 2019-08-22 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
US20210000895A1 (en) * 2018-03-01 2021-01-07 Rhode Island Hospital Exosome targeting of cd4+ expressing cells
GB201809622D0 (en) 2018-06-12 2018-07-25 Evox Therapeutics Ltd Engineering extracellular vesicles for affinity purification
JP2021533834A (ja) 2018-08-14 2021-12-09 エバーサイト・ゲーエムベーハー 標的特異的細胞外小胞
WO2020043750A1 (en) 2018-08-28 2020-03-05 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
EP3860626A2 (en) * 2018-10-04 2021-08-11 Exogenus Therapeutics, SA Compositions comprising small extracellular vesicles derived from umbilical cord blood mononuclear cells with anti-inflammatory and immunomodulatory properties and process for obtaining them
CA3120093A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
EP3654215B1 (en) 2018-11-15 2021-06-30 Sternum Ltd. Applying control flow integrity verification in intermediate code files
WO2020154746A1 (en) * 2019-01-25 2020-07-30 Mantra Bio, Inc. Skeletal muscle targeting moieties and uses thereof
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
CA3144267A1 (en) * 2019-06-21 2020-12-24 Entelexo Biotherapeutics Inc. Platforms, compositions, and methods for therapeutics delivery
WO2021034131A1 (ko) * 2019-08-20 2021-02-25 (주)메디톡스 표적 단백질로서 il-1 저해제를 코딩하는 폴리뉴클레오티드를 포함하는 재조합 세포로부터 유래한 세포외 소낭 및 그의 용도
EP4097474A4 (en) 2020-01-27 2024-03-27 Mantra Bio, Inc. NON-NATURALLY OCCURRING VESICLES COMPRISING A CHIMERIC VESICLE LOCALIZATION COMPONENT, METHODS OF PREPARATION AND USES THEREOF
JP2023512562A (ja) 2020-02-05 2023-03-27 ダイアデム バイオセラピューティクス インコーポレイテッド 人工シナプス
US20230160864A1 (en) * 2020-02-12 2023-05-25 President And Fellows Of Harvard College Methods of measuring and purifying extracellular vesicles
US20230226118A1 (en) * 2020-03-17 2023-07-20 Ohio State Innovation Foundation Designer extracellular vesicles for treating excitotoxicity
CN111529505B (zh) * 2020-03-25 2023-04-11 西安组织工程与再生医学研究所 功能性嵌合凋亡小体及其制备方法和应用
CN111529504B (zh) * 2020-03-25 2023-01-10 西安组织工程与再生医学研究所 功能性嵌合凋亡小体及其制备方法和应用
AU2021247253B2 (en) * 2020-03-31 2024-10-31 Ilias Biologics Inc. Use of exosome-based delivery of NF-κB inhibitors
KR102636371B1 (ko) * 2020-04-10 2024-02-19 한국과학기술연구원 신규 재조합 엑소좀 및 그의 용도
KR102341138B1 (ko) 2020-05-31 2021-12-21 주식회사 엑소코바이오 엑소좀의 막단백질 변이체를 포함하는 엑소좀 및 이의 제조방법
CN111588704B (zh) * 2020-07-01 2023-04-11 西安组织工程与再生医学研究所 靶向响应性释放系统及其制备方法和应用
CN111803617A (zh) * 2020-07-16 2020-10-23 卡杜兰(广州)生命基因工程科技有限公司 一种内载微囊的干细胞系统与制备方法
US12042545B2 (en) 2020-10-14 2024-07-23 The Board Of Trustees Of The University Of Illinois Encapsulated extracellular vesicles
WO2022087505A1 (en) * 2020-10-23 2022-04-28 Strm.Bio Incorporated Compositions and methods related to megakaryocyte-derived extracellular vesicles for treating myeloproliferative neoplasms
KR20220101559A (ko) 2021-01-11 2022-07-19 주식회사 엑소코바이오 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법
KR20220106696A (ko) 2021-01-21 2022-07-29 주식회사 엑소코바이오 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도
CN113166724A (zh) * 2021-03-30 2021-07-23 深圳市创生芯科生物科技有限公司 从iPSC及其衍生物制备用于任何临床用途的外泌体的方法
JP2024513087A (ja) 2021-04-07 2024-03-21 アストラゼネカ・アクチエボラーグ 部位特異的改変のための組成物及び方法
BR112023021834A2 (pt) * 2021-04-23 2024-02-06 Avulotion Vesículas extracelulares de células estromais mesenquimais para tratamento de doenças
CN113616811B (zh) * 2021-08-18 2023-12-05 南京中医药大学 一种载脂蛋白修饰的融合型多功能纳米囊泡及其制备方法和应用
GB2631171A (en) 2021-12-03 2024-12-25 Broad Inst Inc Compositions and methods for efficient in vivo delivery
CN114848608B (zh) * 2022-05-17 2024-01-30 东南大学 一种蛋白或多肽递送载体及其制备方法与应用
EP4282951A1 (en) * 2022-05-25 2023-11-29 École Nationale Vétérinaire, Agroalimentaire et de l'Alimentation, Nantes-Atlantique (ONIRIS) Method for obtaining extracellular vesicles from beta cells
US20240018480A1 (en) * 2022-07-15 2024-01-18 ExoTop Theragnostics Inc. Enhancement of extracellular vesicle production by lysosome inhibitor
CN117802045A (zh) * 2022-09-30 2024-04-02 北京恩康医药有限公司 一种工程化细胞外囊泡的构建及其应用
CN116327978A (zh) * 2023-04-20 2023-06-27 常州市武进人民医院(常州市第八人民医院) 一种靶向肝星状细胞的血小板外囊泡递药系统、制备方法及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
JP3693209B2 (ja) * 1996-04-11 2005-09-07 三菱化学株式会社 閉鎖小胞の製造方法
EE200000574A (et) * 1998-03-31 2002-10-15 Dupont Pharmaceuticals Company Farmatseutilised ühendid angiogeensete häirete kuvamiseks
FR2788780B1 (fr) * 1999-01-27 2001-03-30 Ap Cells Inc Procede de preparation de vesicules membranaires
US20040241176A1 (en) 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
CA2454756C (en) † 2001-08-17 2014-02-18 Anosys, Inc. Methods and compounds for the targeting of protein to exosomes
PL369953A1 (en) * 2001-10-13 2005-05-02 Asterion Limited Glycosylphosphatidylinositol containing polypeptides
WO2006079068A2 (en) * 2005-01-20 2006-07-27 University Of Rochester Compositions and methods for studying and treating inflammatory diseases and disorders
US8455188B2 (en) 2007-01-26 2013-06-04 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
GB2463401B (en) † 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
EP2408474B1 (en) 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
ES2749393T3 (es) 2009-04-17 2020-03-20 Univ Oxford Innovation Ltd Composición para entrega de material genético
WO2011097633A2 (en) * 2010-02-08 2011-08-11 Board Of Regents, The University Of Texas System Egf receptor mimicking peptides
SG190450A1 (en) 2010-12-20 2013-06-28 Agency Science Tech & Res Method of purifying exosomes
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US20130028895A1 (en) * 2011-07-27 2013-01-31 Gerald Wulf Exosome inhibiting agents and uses thereof
GB201121070D0 (en) * 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
GB201121069D0 (en) 2011-12-07 2012-01-18 Isis Innovation Delivery system
ES2662326T5 (es) 2013-04-12 2021-08-04 Evox Therapeutics Ltd Vesículas de suministro terapéutico

Also Published As

Publication number Publication date
WO2014168548A2 (en) 2014-10-16
AU2014251388B2 (en) 2017-03-30
ES2662326T3 (es) 2018-04-06
JP2016516768A (ja) 2016-06-09
EP2983721B1 (en) 2018-02-21
JP6999601B2 (ja) 2022-02-04
JP2022058390A (ja) 2022-04-12
US20200207833A1 (en) 2020-07-02
JP2019167378A (ja) 2019-10-03
US20230111666A1 (en) 2023-04-13
SG11201508433TA (en) 2015-11-27
WO2014168548A3 (en) 2014-12-04
EP2983721A2 (en) 2016-02-17
DK2983721T4 (da) 2021-02-01
DK2983721T3 (en) 2018-03-19
JP6542197B2 (ja) 2019-07-10
CA2910802A1 (en) 2014-10-16
AU2014251388A1 (en) 2015-11-12
US20160137716A1 (en) 2016-05-19
WO2014168548A8 (en) 2015-01-29
EP2983721B2 (en) 2021-01-20
PT2983721T (pt) 2018-03-13
EP3335721A1 (en) 2018-06-20
US11274139B2 (en) 2022-03-15
ES2662326T5 (es) 2021-08-04
US11649272B2 (en) 2023-05-16

Similar Documents

Publication Publication Date Title
HK1257101A1 (zh) 治療性遞送囊泡
HK1221672A1 (zh) 鼻腔給藥
HK1211517A1 (zh) 藥物輸送裝置
IL245544A0 (en) drug delivery system
HK1211520A1 (zh) 藥物輸送裝置
SG11201508647UA (en) Drug delivery device
EP2961469A4 (en) DEVICE FOR DELIVERY OF MEDICAMENT
GB201313782D0 (en) Drug delivery device
HK1211519A1 (zh) 藥物輸送裝置
IL244286A0 (en) Drug delivery device
SG11201600371XA (en) Drug delivery device
GB201308917D0 (en) Delivery
HK1219451A1 (zh) 藥物輸送裝置
HK1219450A1 (zh) 藥物輸送裝置
HK1219682A1 (zh) 藥物輸送裝置
GB201308440D0 (en) Therapeutic
HK1219681A1 (zh) 藥物輸送裝置
HK1219685A1 (zh) 藥物輸送裝置
HK1221412A1 (zh) 囊泡
HK1219680A1 (zh) 藥物輸送裝置
GB2519596B (en) Medicament Delivery device
GB201318668D0 (en) Sonosensitive therapeutic
HK1221921A1 (zh) 藥物輸送裝置
HK1223052A1 (zh) 藥物輸送裝置
IL245007A0 (en) Drug release device